Key Highlights: Implications: Relopduo gives BMS a next‑generation immunotherapy in India’s melanoma market, combining PD‑1 and LAG‑3 blockade to offer materially better pro...
Sun Pharmaceutical Industries is India’s largest pharmaceutical company and among the world’s leading manufacturers of specialty medicines and generic pharmaceuticals. Founded in 1983 by D...
Key Highlights: Implications: By selling the Roorkee and Noida plants (for around ₹56 crore) but retaining brands, trademarks, its Beauty Entrepreneur network, and all commercial operation...
Key Highlights: Implications: Wegovy’s new MASH indication turns semaglutide into a dual liver–weight disease asset in India, opening a large, under-treated fatty liver market (about two i...
Key Highlights: Implications: Qdenga’s approval as India’s first dengue vaccine creates a new prevention market in a country where reported cases have risen about 11‑fold in two decad...
Key Highlights: Implications: Poviztra’s new MASH label lets Emcure plug innovator semaglutide directly into India’s emerging fatty liver treatment market, riding on ESSENCE data (63% stea...
Dr. Reddy’s Laboratories is a leading global pharmaceutical company headquartered in Hyderabad, India, committed to making affordable and innovative medicines accessible worldwide. Established i...
Key Highlights: Implications: RPG Life Sciences is launching India’s first fixed-dose Naproxen + Esomeprazole tablet, Naprosyn ES, to enable safer long-term NSAID use by adding gastroprote...
Key Highlights: Implications: Viatris is selling up to 92 million Biocon shares (about 5.6% of the company) in a secondary sale, so Biocon gets no money from it; the deal is priced at a di...
Key Highlights: Implications: Emcure’s move to take Gennova to 100% ownership and fold it under the “One Emcure” framework tightens control over a strategically important biologi...










